RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal
cells from the side effects of chemotherapy.
PURPOSE: Phase IV trial to study the effectiveness of amifostine in treating patients with
cancer who have neurological changes caused by chemotherapy.
OBJECTIVES: I. Determine the feasibility and tolerability of administering amifostine by
intravenous infusion over 5 minutes in cancer patients undergoing chemotherapy.
OUTLINE: This is an open label, controlled study. Patients receive intravenous amifostine
over 5 minutes 30 minutes prior to chemotherapy. Patients are followed for one month post
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
DISEASE CHARACTERISTICS: Histologically or cytologically proven cancer No brain or other
CNS metastases (including prior treated metastases)
PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-1 Life Expectancy:
Not specified Hematopoietic: Not specified Hepatic: No grade 3 or greater hepatic
dysfunction Renal: No hypercalcemia Cardiovascular: No uncontrolled hypotension Other: Not
pregnant or nursing Effective contraceptive method must be used by fertile patients No
psychosis No severe concurrent illness other than neoplasia No epileptic seizures during
the previous year, migraines, gastrointestinal obstructions, or other causes of vomiting
No prior or concurrent amifostine contraindications No prior known contraindications or
sensitivity to dexamethasone, granisetron, ondansetron, prochlorperazine, diphenhydramine,
cimetidine, or magnesium
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: No prior estrogen within 24 hours of amifostine therapy Radiotherapy:
Not specified Surgery: Not specified Other: No prior alcohol, disulphiram, tetracycline,
or erythromycin within 24 hours of amifostine therapy No prior antiemetics such as
benzodiazepines, antipsychotics, anticonvulsants, or antihistamines within 24 hours of